Abstract
Renal cell carcinoma (RCC) represents the most common type of kidney cancer and, despite the progress of surgical and medical management, is associated with high mortality. In this study, we demonstrate that RCC-related processes change body fluids sphingolipid concentrations, which may be used to monitor tumor presence using non-invasive lipid-based blood and urine tests. We investigate 674 plasma, urine, and tissue samples from 369 RCC patients and controls. For the first time, we show the significant concentration changes of low abundant sulfatides in plasma and urine of RCC patients. Elevated concentrations of lactosylsulfatides, decreased concentrations of sphingomyelins with long saturated N-fatty acyls and sulfatides with hydroxylated fatty acyls are the crucial alternations in RCC. These changes are stage-dependent and are more emphasized in late-stage RCC. Similar trends in body fluids and tissues indicate that RCC widely influences lipid metabolism and highlights the potential of lipidomic profiling for cancer detection.
Competing Interest Statement
M.H., R.J., and D.W. are listed as inventors on the pending patent, A method of diagnosing cancer based on lipidomic analysis of a body fluid (EP18174963.1, filing date 29. 5. 2018), related to this work.
Funding Statement
This work was supported by Czech Science Foundation (GAČR) project No. 18-12204S.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committee of the University Hospital Olomouc and Medical Faculty of Palacký University in accordance with Ethical Principles for Medical Research Involving Human Subjects (Helsinki Declaration).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data necessary to support the conclusions are available in the manuscript or supplementary information. Raw data, instructions for data processing and Excel macro script are available in online open access repository Figshare
